Two supplement meta-analyses, two clean results, and one shared weakness

Two supplement meta-analyses published within four days of each other in October illustrate a structural problem in nutrition evidence better than either does on its own. Both are competently executed. Both report statistically significant, directionally favourable results. And both measure blood markers rather than health.

The ginger analysis

The first pooled 29 randomised controlled trials of ginger (Zingiber officinale) supplementation in adults, searching PubMed, Scopus, Web of Science Core Collection and Google Scholar, with the protocol registered in PROSPERO [s1].

Every outcome moved in the expected direction:

• C-reactive protein: weighted mean difference −0.86 mg/L (95% CI −1.10 to −0.62) [s1]
• Tumour necrosis factor α: −1.90 pg/mL (95% CI −2.61 to −1.18) [s1]
• Interleukin-6: −1.15 pg/mL (95% CI −1.90 to −0.41) [s1]
• Total antioxidant capacity: +0.22 mmol/L (95% CI 0.06 to 0.38) [s1]
• Malondialdehyde: −0.76 µmol/L (95% CI −1.19 to −0.33) [s1]
• Superoxide dismutase: +48.12 U/L (95% CI 30.57 to 65.58) [s1]

Six for six, all confidence intervals excluding zero. The authors report that the effect on IL-6 associates with dosage and duration in a non-linear fashion, and that ginger may improve these biomarkers particularly in individuals with underlying health conditions [s1]. They also state plainly that heterogeneity among studies was high and that findings should be interpreted cautiously [s1].

The omega-3 analysis

The second pooled 21 randomised trials, roughly 1,950 participants in total, of marine-derived omega-3 supplementation — EPA and DHA — in adults with metabolic syndrome or its components [s2]. Databases were searched to June 2024, quality was assessed with the Cochrane Risk-of-Bias Tool, and trials were categorised by dose (low, under 1,000 mg/day; medium, 1,000–2,000 mg/day; high, over 2,000 mg/day) and by duration (short-term, up to 8 weeks; medium-term, over 8 to 12 weeks; long-term, over 12 weeks) [s2].

Triglycerides showed the largest and most consistent response. The biggest reductions came in the high-dose long-term group (−56.78 ± 3.44 mg/dL) and the high-dose short-term group (−50.873 ± 3.04 mg/dL), with the medium-duration high-dose group at −41.536 ± 4.12 mg/dL [s2]. Medium-dose results were smaller: −24.93 ± 0.464 mg/dL at medium duration and −31.843 ± 0.46 mg/dL at long duration, all at p < 0.001 [s2].

The dose-duration structure is the paper's contribution. It is also the clearest signal in it — a roughly 50 mg/dL triglyceride reduction at high dose is a large biochemical effect, consistent with what is already known about the triglyceride-lowering action of EPA and DHA.

The endpoint each one is missing

Neither analysis measured a clinical event. Not a myocardial infarction, not a stroke, not a diagnosis, not a hospitalisation, not a death.

That is not a criticism of the authors — they pooled what the underlying trials measured, and the underlying trials measured biomarkers. It is a description of the evidence base.

The gap matters because biomarker endpoints and clinical endpoints have come apart before, in exactly this literature. Lowering triglycerides is not the same as preventing cardiovascular events; the history of triglyceride-targeting drugs contains several agents that reliably moved the number without moving outcomes. Reducing CRP is not the same as reducing the disease processes that CRP indexes. An inflammatory marker is a signpost, and moving a signpost does not move the road.

The two papers also share a second limitation. Neither can distinguish an effect on people who are ill from an effect on people who are well. The ginger review notes its effect appears strongest in individuals with underlying health conditions [s1]; the omega-3 review recruited adults who already had metabolic syndrome or its components [s2]. Neither speaks to a healthy adult taking a supplement as a preventive measure, which is the dominant real-world use case.

Heterogeneity is not a footnote

Both analyses pool trials that differ in preparation, dose, duration, population and assay. The ginger review says so directly and attaches a caution to its own findings [s1]. The omega-3 review handles the problem structurally, by stratifying rather than averaging across dose and duration [s2], which is the better approach and is why its triglyceride result reads as more interpretable.

Where heterogeneity is high, the pooled point estimate describes an average of dissimilar experiments. The confidence interval around it describes sampling precision, not the range of plausible effects in any individual. A reader who takes −0.86 mg/L of CRP as a personal forecast has over-read the statistic.

How to read a supplement meta-analysis

Three questions do most of the work. Is the endpoint a marker or an event? Was the comparison against placebo in people already receiving standard care, or against nothing? And does the pooled estimate come from trials similar enough that averaging them means anything?

On the first question, both October papers answer "marker." On the second, both are placebo-controlled, which is a genuine strength. On the third, the ginger analysis flags high heterogeneity itself [s1], and the omega-3 analysis mitigates it by stratifying [s2].

What to watch

Clinical-endpoint trials of dietary supplements are expensive and rare, and there is little commercial incentive to run them where the product can already be sold without one. The realistic path to better evidence runs through longer trials in defined patient populations with pre-registered clinical outcomes — the kind of study that turns a plausible biochemical effect into a health claim, or retires it.

This article describes published research and is not medical advice. Supplement doses, interactions with prescribed medicines and individual suitability are clinical questions.

Sources

• [s1] Antioxidant and anti-inflammatory effects of ginger supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials — Inflammopharmacology, published online 22 October 2025. https://doi.org/10.1007/s10787-025-01994-6
• [s2] Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Nutrients, 18 October 2025. https://doi.org/10.3390/nu17203279